Main Conference – Day 1Wednesday, 18 March 2026 - CET (Central European Time, GMT+01:00)

• Cell-free RNAs (cfRNAs), stabilized by extracellular vesicles (EVs), lipoproteins, and RNA-binding proteins (RBPs), are emerging as key players in RNA therapeutics and biomarker research, with a focus on their role in cell-to-cell communication.• Recent findings emphasize the importance of RBPs in cfRNA biology, highlighting their potential to enhance stability, specificity, and targeted uptake for next-generation RNA therapeutics. cfRNAs also show promise as non-invasive biomarkers for real-time monitoring of therapeutic efficacy and optimizing personalized treatments.• Integrating cfRNA discoveries into RNA therapeutic pipelines offers the potential to advance individualized treatment strategies, improve patient outcomes, and set new standards in RNA-based medicine.